MetaCap

Invivyd Inc. (IVVD)

NASDAQ: IVVDHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD

0.4127-0.0332 (-7.45%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

IVVD stock chart

Technical analysis

Key statistics

All statistics
Market cap
$122.01M
EPS (TTM)
-$0.38
52-week range
0.4127 – 3.01
Day range
0.4127 – 0.4669
Volume / Avg
5.30M / 5.20M
Beta
—

52-week range

$0.4127$3.01

IVVD stock today

On Nov 20, IVVD ended the session at $0.4127, shedding $0.0332 (7.45%), versus the S&P 500's 3.70% decline. Shares are 86.3% below their 52-week high of $3.01, set on Dec 23, 2025 and 0.0% above the 52-week low of $0.4127, near the bottom of the past year's range. IVVD is down 83.3% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 83.5%.

Invivyd has posted a net loss over the last twelve months (EPS of -$0.38), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About Invivyd

Company profile

Invivyd, Inc., together with its subsidiaries, engages in the research, development, commercialization, and sale of antibody therapies for the prevention and treatment of viral infectious diseases in the United States. The company offers Pemivibart, a half-life extended investigational monoclonal antibody for the pre-exposure prophylaxis prevention of COVID-19 in adults and adolescents through injection under the PEMGARDA brand. It also develops VYD2311, a monoclonal antibody, which is in Phase III clinical trial for the prevention and treatment of SARS-CoV-2 virus; and VBY329, a monoclonal antibody, which is in pre-clinical trial stage for the prevention and treatment of respiratory syncytial virus and measles in neonates, infants, and children.

Industry
Biotechnology: Biological Products (No Diagnostic Substances)
CEO
Mr. Marc William Elia
Headquarters
New Haven, CT
Employees
122
IPO year
2021

Financial highlights

Full financials

In fiscal 2025, Invivyd generated $53.4 million in revenue, up 110.5% from fiscal 2024, its 2nd consecutive year of revenue growth. Invivyd reported a net loss of $52.5 million, compared with a loss of $169.9 million a year earlier. Operating margin was -104.0%.

Invivyd annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue$53.43M$25.38M$0——
Growth+110.47%————
Net income$-52.49M$-169.93M$-198.64M$-241.32M$-226.79M
EPS (diluted)$-0.30$-1.43$-1.81$-2.23$-5.32

Analyst forecast

Forecast

Consensus (3 analysts)

strong_buy

Avg. price target

$10.00+2323.07%

  • Strong buy 0
  • Buy 3
  • Hold 0
  • Sell 0
  • Strong sell 0

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 16, 2026
EPS actual vs est.
$-0.10 vs $-0.11
Surprise
+9.09%

IVVD news

All IVVD news

Invivyd peers

Health Care sector
IVVD peer companies
CompanyPrice% ChgMarket capCompare
HUMAHumacyte Inc.0.4454-17.90%$123.73Mvs IVVD
CMPXCompass Therapeutics Inc.0.6882+1.43%$123.94Mvs IVVD
ENGNenGene Therapeutics Inc.1.74-1.14%$116.61Mvs IVVD
ARMPArmata Pharmaceuticals Inc.3.03+1.68%$112.69Mvs IVVD
FATEFate Therapeutics Inc.0.919-9.01%$111.82Mvs IVVD
CRDLCardiol Therapeutics Inc. Class A0.8626-2.28%$110.14Mvs IVVD
TARAProtara Therapeutics Inc.2.28-5.00%$140.38Mvs IVVD
STROSutro Biopharma Inc.8.60-1.38%$142.77Mvs IVVD

Indexes, lists and sector

Invivyd stock FAQ

What is Invivyd's stock price today?

IVVD last traded at $0.4127 as of Nov 20, 4:00 PM EST, down 7.45% on the day. Prices are delayed at least 15 minutes.

Who is Invivyd's CEO?

Mr. Marc William Elia is the chief executive officer of Invivyd Inc., which has about 122 employees.

What is the IVVD 52-week high?

The 52-week high for IVVD is $3.01 and the 52-week low is $0.4127. The stock is currently 86.3% below its high.

Compare IVVD